Gema Ariceta

Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

Timothy H.J. Goodship, H. Terence Cook, Fádi Fakhouri et al. · Kidney International · 2016 · 695 citations · Full text

Medicine, Nephrology, Pathology +17

Mutations in the Tight-Junction Gene Claudin 19 (CLDN19) Are Associated with Renal Magnesium Wasting, Renal Failure, and Severe Ocular Involvement

Martin Konrad, André Schaller, Dominik Seelow et al. · The American Journal of Human Genetics · 2006 · 522 citations · Full text

Medicine, Genetics, Molecular Genetics +15

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Éric Rondeau, Marie Scully, Gema Ariceta et al. · Kidney International · 2020 · 219 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome

Franz Schaefer, Gianluigi Ardissino, Gema Ariceta et al. · Kidney International · 2018 · 179 citations

Medicine, Genetics, Nephrology +14

Effectiveness of mycophenolate mofetil in C3 glomerulonephritis

Cristina Rabasco, Teresa Cavero, Elena Román et al. · Kidney International · 2015 · 170 citations

Medicine, Nephrology, Pharmacotherapy +12